Hayat Pharmaceutical Industries Co (AMM:HPIC) Change In Receivables: JOD-1.56 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMM:HPIC Hayat Pharmaceutical Industries Co AMM:HPIC
47 GF Score
Price JOD3.20
! 8 Warning Signs
View Full Analysis

What is Hayat Pharmaceutical Industries Co Change In Receivables?

Hayat Pharmaceutical Industries Co AMM:HPIC +1.27% 47 Change In Receivables is JOD-1.56 Mil as of Jun. 2026. GuruFocus rates AMM:HPIC with a GF Score™ of 47/100. The stock has 8 warning signs investors should review.

Hayat Pharmaceutical Industries Co's change in receivables for the quarter that ended in Jun. 2026 was JOD-1.04 Mil. It means Hayat Pharmaceutical Industries Co's Accounts Receivable increased by JOD1.04 Mil from Mar. 2026 to Jun. 2026 .

Hayat Pharmaceutical Industries Co's change in receivables for the fiscal year that ended in Dec. 2025 was JOD-1.47 Mil. It means Hayat Pharmaceutical Industries Co's Accounts Receivable increased by JOD1.47 Mil from Dec. 2024 to Dec. 2025 .

Hayat Pharmaceutical Industries Co's Accounts Receivable for the quarter that ended in Jun. 2026 was JOD4.48 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Hayat Pharmaceutical Industries Co's Days Sales Outstanding for the three months ended in Jun. 2026 was 91.82.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Hayat Pharmaceutical Industries Co's liquidation value for the three months ended in Jun. 2026 was JOD5.69 Mil.

Hayat Pharmaceutical Industries Co  (AMM:HPIC) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Hayat Pharmaceutical Industries Co's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=4.479/4.451*91
=91.82

2. In Ben Graham's calculation of liquidation value, Hayat Pharmaceutical Industries Co's accounts receivable are only considered to be worth 75% of book value:

Hayat Pharmaceutical Industries Co's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=8.062-7.569+0.75 * 4.479+0.5 * 3.673
=5.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hayat Pharmaceutical Industries Co Change In Receivables Related Terms

Hayat Pharmaceutical Industries Co Change In Receivables Historical Data

* Premium members only.

The historical data trend for Hayat Pharmaceutical Industries Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hayat Pharmaceutical Industries Co Change In Receivables Chart

Hayat Pharmaceutical Industries Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.54 -1.91 -0.33 -0.98 -1.47

Hayat Pharmaceutical Industries Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.72 -0.87 -0.77 1.12 -1.04
AMM:HPIC
47GF Score
Hayat Pharmaceutical Industries Co AMM:HPIC
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hayat Pharmaceutical Industries Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was JOD-1.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of JOD-1.56 Mil mean?
Hayat Pharmaceutical Industries Co (AMM:HPIC) has a Change In Receivables of JOD-1.56 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Hayat Pharmaceutical Industries Co and its competitors.
Is Hayat Pharmaceutical Industries Co's Change In Receivables too high?
Hayat Pharmaceutical Industries Co's current Change In Receivables is JOD-1.56 Mil. Overall, Hayat Pharmaceutical Industries Co has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Hayat Pharmaceutical Industries Co's Change In Receivables compare to ZTS and UTHR?
Hayat Pharmaceutical Industries Co's Change In Receivables of JOD-1.56 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Hayat Pharmaceutical Industries Co and its competitors. Hayat Pharmaceutical Industries Co's current Change In Receivables is JOD-1.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hayat Pharmaceutical Industries Co stock overvalued right now?
Hayat Pharmaceutical Industries Co (AMM:HPIC) has a current Change In Receivables of JOD-1.56 Mil. The current Change In Receivables is JOD-1.56 Mil. Hayat Pharmaceutical Industries Co's overall GF Score™ is 47/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Hayat Pharmaceutical Industries Co (AMM:HPIC), the current Change In Receivables is JOD-1.56 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hayat Pharmaceutical Industries Co Business Description

Address Mohammed Ali Alkurdi St. Al-Rajeeb Amman, 1564 Amman, Amman, JOR, 11118
Hayat Pharmaceutical Industries Co is a Jordan based pharmaceutical manufacturing company. The princapal activity is producing human and veterinary medicines in all its forms and medical stickers and stockings, in addition to the production of medical supplies, body care lotions, cosmetics, sutures and initiating marketing campgains as well as import and export operations. Its products include Cardiovascular system, Infectious disease, Dermatology, Gastrointestinal system, Inner Ear & Balance, Men's Health, Neurology, Vitamins & Supplements, Women's Health, and Respiratory system. The operations business operating within one geographic sector which is the Hashemite Kingdom of Jordan.
47GF Score

Get the complete analysis for AMM:HPIC

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

JOD3.20
Price